Award details

A Chemical Technology to Generate Homogeneous Antibody-Drug-Conjugates (ADCs) and Bispecifics

Reference	BB/L024349/1
Principal Investigator / Supervisor	Professor James Baker
Co-Investigators / Co-Supervisors	Professor Stephen Caddick, Professor Kerry Chester
Institution	University College London
Department	Chemistry
Funding type	Research
Value (£)	480,085
Status	Completed
Type	Research Grant
Start date	31/07/2014
End date	30/01/2017
Duration	30 months

Abstract

unavailable

Summary

Using antibodies as therapeutics and diagnostics is one of the most promising areas of research into new healthcare products. Antibodies represent the fastest growing class of therapeutics, with over 20 approved for clinical use to date and over 150 in clinical development. It is estimated that the global market for antibody therapeutics is currently around $50 billion. Two particularly promising classes of antibody based therapeutics are antibody-drug-conjugates (ADCs) and bispecifics, commonly referred to as 'magic-bullet' therapies due to their ability to seek and destroy just diseased cells within the body (e.g. cancer cells). However, a major hindrance to the area is the lack of suitable chemical methods for the construction of homogeneous, well defined, antibody conjugates. Here we propose to exemplify a powerful new chemical technology that we have developed to overcome these limitations, to enable the design of superior next generation ADCs and bispecifics.

Committee	Not funded via Committee
Research Topics	Immunology, Pharmaceuticals
Research Priority	X – Research Priority information not available
Research Initiative	Follow-On Fund Super (SuperFOF) [2012-2015]
Funding Scheme	X – not Funded via a specific Funding Scheme

I accept the terms and conditions of use (opens in new window)

export PDF file

back to list new search